TY - JOUR
T1 - Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells
AU - Keda, Ryujii
AU - Vermeulen, Lee C.
AU - Lau, Elim
AU - Jiang, Zhisheng
AU - Kavanaugh, Shannon M.
AU - Yamada, Katsushi
AU - Kolesar, Jill M.
PY - 2011/1
Y1 - 2011/1
N2 - Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is an effective therapy for non-small cell lung cancer (NSCLC). However, resistance to erlotinib reduces its efficacy. To investigate the basis of erlotinib resistance, we isolated erlotinib-resistant human NSCLC A549 cells, termed A549/ER cells. The A549/ER cells were found to be resistant to erlotinib, as well as paclitaxel and gemcitabine. We then performed a PCR array to investigate the resistance to erlotinib in A549/ER cells. EGFR expression in A549/ER cells was decreased compared to A549 cells. The expression of fibroblast growth factor 2 (FGF2) and p21 in A549/ER was increased when compared to A549 cells. Our results suggest that the down-regulation of EGFR and up-regulation of FGF2 is related to resistance to erlotinib in A549/ER cells.
AB - Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is an effective therapy for non-small cell lung cancer (NSCLC). However, resistance to erlotinib reduces its efficacy. To investigate the basis of erlotinib resistance, we isolated erlotinib-resistant human NSCLC A549 cells, termed A549/ER cells. The A549/ER cells were found to be resistant to erlotinib, as well as paclitaxel and gemcitabine. We then performed a PCR array to investigate the resistance to erlotinib in A549/ER cells. EGFR expression in A549/ER cells was decreased compared to A549 cells. The expression of fibroblast growth factor 2 (FGF2) and p21 in A549/ER was increased when compared to A549 cells. Our results suggest that the down-regulation of EGFR and up-regulation of FGF2 is related to resistance to erlotinib in A549/ER cells.
KW - Epidermal growth factor receptor
KW - Erlotinib
KW - Fibroblast growth factor 2
KW - P21
UR - http://www.scopus.com/inward/record.url?scp=78751549460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78751549460&partnerID=8YFLogxK
U2 - 10.3892/ol.2010.198
DO - 10.3892/ol.2010.198
M3 - Article
AN - SCOPUS:78751549460
SN - 1792-1074
VL - 2
SP - 91
EP - 94
JO - Oncology Letters
JF - Oncology Letters
IS - 1
ER -
